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Abstract: Hepatocellular carcinoma (HCC) is a very rare entity in children, making it nearly 
impossible to orchestrate Phase II/III studies even as multinational cooperative trials. In con-
trast to adults, nearly 50% of the children have a response (α-fetoprotein decline and/or tumor 
shrinkage) to chemotherapeutic agents such as cisplatin and doxorubicin (PLADO), demon-
strating that HCC in childhood can be chemotherapy sensitive. As a result, the main treatment 
options in pediatric HCC focus on systemic drug therapies and resection as the central therapy. 
In nonmetastatic patients with complete resection upfront, the 5-year event-free survival and 
overall survival has reached 80%–90%. In almost all reported studies, children received adju-
vant chemotherapy (mostly PLADO), but it has never been proven that postoperative chemo-
therapy is superior to observation. No data are available for the effects of sorafenib. The 3-year 
survival is <20% in children with unresectable HCC independent of the chemotherapy given 
preoperatively. Currently, PLADO in combination with sorafenib is recommended with the 
goal of achieving operability status. Alternatively, data are promising for the combination of 
sorafenib with gemcitabine and oxaliplatin. For children with nonresectable and nonmetastastic 
liver tumors, it has been shown that the Milan criteria regarding liver transplantation are not 
applicable – individual decisions have to be made. Transarterial chemoembolization could be 
offered to patients with chemotherapy-resistant liver tumors for palliative care or potentially 
to achieve surgical resectability, and therefore cure. Information about the feasibility or effects 
of new agents or approaches as discussed in adult HCC patients is not available for childhood 
HCC. Research has to be done for characterizing the molecular and genomic mechanisms of 
pediatric HCC to support the development of novel therapeutic approaches and the implementa-
tion of personalized medicine.
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Introduction
Primary malignant liver tumors are rare in childhood with an incidence of about 1.6 
cases per million children (0–14 years).1,2 While hepatoblastoma (HB) represents 80% 
of the hepatic-related cancer affecting children predominantly between 6 months and 3 
years, hepatocellular carcinoma (HCC) is more uncommon, with incidence increasing 
with age. Only about 0.5%–1% of all pediatric tumors are HCC.1,2 In hepatoblastoma, 
event-free survival (EFS) and overall survival (OS) was increased from roughly 30% 
in the 1970s to 70%–90% these days, especially due to advances of chemotherapy 
regimens and surgical approaches.3 In HCC, the results with unresectable tumor 
especially are rather dismal.
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Contrary to adults, in the majority of children or adoles-
cents, no etiologic factors can be detected. However, in areas 
with a high prevalence of hepatitis B virus (HBV) infection 
rate, the lifetime risk of HCC in chronic HBV carriers is 
estimated to be 10%–25%.4 For example, in Taiwan and 
Hong Kong, 100% and 64%, respectively, of all children 
with HCC were chronic HBV carriers. It can be expected 
that universal newborn vaccination will have an effect in 
reducing the incidence of HCC.5,6 Only a minority of HCC 
cases are associated with cirrhosis or other chronic liver dis-
eases such as glycogen storage disease type III, tyrosinemia 
type I, Wilson disease, or biliary atresia. This indicates that 
the pathogenesis of HCC in childhood is different compared 
with that in adults.7–9
Management of HCC remains difficult since complete 
surgical resection is fundamental for cure. However, in pedi-
atric HCC, <20% of the patients are considered eligible for 
initial resection. Various studies have been conducted using 
different combinations of chemotherapeutic agents to reduce 
tumor load, thereby helping patients become suitable candi-
dates for resection. Historically, HCC patients were treated 
with the same protocols as HB patients, and so, primarily, 
cisplatin, doxorubicin, carboplatin, 5-fluorouracil, and vin-
cristine were used.1,10 However, to date, there is no convincing 
data that this approach results in a benefit for survival.
The 3-year EFS and OS for children with complete 
tumor excision upfront and two courses of carboplatin 
(200 mg/m2/d × 4) and etoposide (100 mg/m2/d × 4) were 
72% and 89%, respectively, in the HB99 study (1999–2008)11 
conducted by the German Society for Pediatric Oncology 
and Hematology (GPOH). However, the prognosis remained 
poor, with 3-year EFS and OS rates of 12% and 20% in 
those patients who had inoperable or metastatic disease. 
Intensifying preoperative chemotherapy with two courses 
of carboplatin and etoposide followed by two courses of 
high-dose carboplatin (500 mg/m2/d × 4) and etoposide 
(300 mg/m2/d  × 4) with autologous stem cell transplanta-
tion did not translate into a satisfactory operability rate, 
EFS, or OS.
Similar findings were reported by the North American 
Intergroup Hepatoblastoma Study (INT-0098) (1989–1992).12 
The 5-year EFS (OS) for pediatric patients (26/46 patients 
≥10 years) with inoperable tumor upfront was 8% (23%), 
and for those with metastases it was 0% (19%). There was no 
difference based on whether the children received cisplatin 
(90 mg/m2 on d0) and doxorubicin (20 mg/m2/d × 4 from d2) 
or cisplatin (90 mg/m2 on d0), 5-fluorouracil (600 mg/m2 on 
d2), and vincristine (1.5 mg/m2 on d2).
Importantly, the first International Society of Pediatric 
Oncology Liver Tumor Study (SIOPEL-1 study, 1990–1994)1 
demonstrated that HCC in childhood (4–15 years, median: 
12 years) can be chemotherapy sensitive. They proved this 
by showing that 49% of the children responded to cisplatin 
(80 mg/m2 on d1) and doxorubicin (30 mg/m2/d on d2+3) 
(PLADO). However, taking into consideration that complete 
resection is the cornerstone of cure, only 36% had complete 
tumor excision, and so the 5-year EFS was only 17%. The 
next attempt (SIOPEL-2 study, 1995–1998)10,13 tried was 
rapidly switching between cisplatin (80 mg/m2 on d1) and 
carboplatin (500 mg/m2 on d1)/doxorubicin (30 mg/m2/d on 
d2+3) (SuperPLADO) every 14 days, but this did not improve 
the response rate after preoperative chemotherapy (46%), and 
therefore also not 3-year OS (22%).
Thus, to date, for children with inoperable liver tumor 
and/or with metastases, the complete resection (and so the 
EFS and OS) have not improved although different strategies 
have been attempted.
Sorafenib is an inhibitor of several tyrosine protein 
kinases such as VEGFR, PDGFR, and Raf kinases.14–16 In 
preclinical models, sorafenib demonstrated antitumor activ-
ity alone and in combination with, for instance, doxorubicin, 
gemcitabine, and cisplatin.17,18 In adult patients with advanced 
HCC, sorafenib significantly improved both time to tumor 
progression and OS from a median of 2.8 to 5.5 months 
and from 7.9 to 10.7 months, respectively, compared with 
placebo. The most important grade 3 adverse effects were 
diarrhea, hand–foot skin reaction, and fatigue.19 Therefore, 
sorafenib has become the standard therapy for adult patients 
with HCC.20 Furthermore, in a randomized, double-blind, 
Phase II study combining sorafenib with doxorubicin, the 
progression-free survival (PFS) was significantly better 
in patients receiving sorafenib and doxorubicin than in 
those receiving doxorubicin and placebo (median: 4.8 vs 
8.6 months).21,22 Moreover, tumor reduction was achieved 
in 62% vs 29% of the patients. This effect could be due to 
the fact that combining sorafenib with doxorubicin trans-
lated into an increased mean values of doxorubicin C
max
 and 
area under the curve by 33% and 21%, respectively.23 In the 
recent study with 12 children (seven with unresectable liver 
tumor, age 7–16 years), it was demonstrated that sorafenib 
(244–602 mg/m2/d, median: 288 mg/m2/d) added to PLADO 
is a promising new therapeutic option with hand–foot skin 
reaction being the most relevant toxicity.24 With this combina-
tion, four of the seven children with inoperable liver tumor 
achieved a partial response (PR), two a stable disease, and 
one a progression. Three patients were alive without evidence 
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of tumor after complete tumor excision at 12 months (with 
second-line chemotherapy after two courses sorafenib and 
PLADO), 12 months, and 18 months (both patients had six 
courses sorafenib and PLADO), respectively, after primary 
diagnosis. The elevated α-fetoprotein levels seen in four 
patients at diagnosis markedly declined after two courses of 
therapy. Since then, some pediatric liver tumor specialists 
have recommended PLADO with sorafenib as a “standard” 
chemotherapy.
Thus, there are big challenges to be solved for pediatric 
patients with HCC, namely: 1) What is the standard-of-
care in children with newly diagnosed HCC with complete 
resection upfront: observation vs sorafenib vs PLADO vs 
PLADO and sorafenib? 2) What are the therapeutic options 
in newly diagnosed patients with unresectable tumors and/
or metastatic disease? 3) Are there new approaches on the 
horizon for HCC in children? 4) Must the Milan criteria for 
a liver transplantation be strictly adhered to? and 5) Does 
transarterial chemoembolization (TACE) play a role in 
pediatric patients?
Standard-of-care with complete resection 
upfront: observation vs sorafenib vs 
PLADO vs PLADO and sorafenib?
Katzenstein et al12 reported an 88% 5-year EFS in patients 
with completely resected HCC receiving either cisplatin, 
5-fluorouracil, and vincristine or PLADO (n=8). The 
 German HB99 study11 used two cycles of carboplatin/eto-
poside postoperatively, which translated into 5-year EFS 
and OS probabilities of 72% and 89% (n=14), respectively. 
Thus, there seems to be no difference in survival based on 
the chemotherapy used. Whether postoperative sorafenib 
has a survival benefit remains unclear. In adults, it was 
recently shown that sorafenib is not effective as an adjuvant 
treatment following resection or ablation.25 An enhanced 
chemotherapeutic response to sorafenib and PLADO was 
demonstrated in the small series of patients with advanced 
HCC (PR in four out of seven). However, further data 
regarding sorafenib are urgently needed in the pediatric 
HCC population.24
The problem is that it is impossible to realize Phase II to 
III studies in an entity as rare as HCC in childhood. In the 
SIOPEL 1, 2, and 3 studies1,10 recruiting patients between 
1990 and 2004, 15/121 had an HCC with complete resection 
at diagnosis. Internationally, the estimated number of primary 
resectable patients would be about 10/year. With such low 
numbers, a study randomizing patients after upfront complete 
surgical resection to observation vs sorafenib vs PLADO vs 
PLADO and sorafenib, and even to a two-arm study, will 
never be feasible within an adequate amount of time.
Thus, only recommendations can be given. Pediatric 
liver tumor specialists currently recommend that children 
with HCC should receive PLADO with or without sorafenib, 
as more intensive regimens have not yielded better results. 
But the role of postoperative chemotherapy and the amount 
(PLADO for two or four cycles? sorafenib at all or for 6 or 
12 months?) for a stage I disease that has demonstrated che-
motherapeutic sensitivity in pediatric patients are unknown.
Current therapeutic options in newly 
diagnosed patients with unresectable 
tumors and/or metastatic disease
Pediatric patients with unresectable or primarily metastatic 
HCC do not survive unless the disease can be rendered 
resectable. Given preexisting evidence that pediatric HCC 
is chemotherapy responsive in nearly 50% of the patients 
(Table 1), PLADO has been established as the standard 
chemotherapy. Intensification of platinum and doxorubicin 
agents, as in the SIOPEL 2 and 3 studies,13 did not result in 
improved survival. However, 5-year EFS rates still remain 
between 10%–34% since response mostly does not translate 
into complete surgical resection. Better tumor shrinkage is 
needed to facilitate surgery. Hopefully, sorafenib in addition 
to PLADO improves the resectability rate, EFS, and OS.24
In a recently published multicenter study from France, 
204 adults with advanced HCC received gemcitabine 
(1,000 mg/m² on d1) and oxaliplatin (100 mg/m² on d2) 
(GEMOX), with promising response and tumor control 
rates of 22% and 66%, respectively.26 In 44% of the patients, 
grade 3–4 toxicities were reported, especially neutropenia, 
Table 1 Response to chemotherapy and resection rates in 
different pediatric trials
Trial Chemotherapy PR rate Resection 
rate
INT 009812 PLADO versus C5v 21% (8/38) 5% (2/38)
SIOPEL 11 PLADO 49% (18/32) 63% (12/19)
SIOPEL 210 Cisplatin, carboplatin, 
doxorubicin 
50% (29/58) 44% (14/32)
HB99 
(GPOH)11
Carboplatin and etoposide 
with autologous stem cell 
transplantation  
47% (7/15) 36% (8/22)
PLADO/
sorafenib24
Cisplatin, doxorubicin, sorafenib 57% (4/7) 29% (2/7)
Notes: PR was defined according to the RECIST criteria as an at least 30% decrease 
in tumor volume by imaging modalities associated with a decreasing α-fetoprotein 
value.
Abbreviations: PR, partial response; PLADO, cisplatin and doxrubicin; RECIST, 
Response Evaluation Criteria in Solid Tumors
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 thrombocytopenia, neurotoxicity, and diarrhea. In a retro-
spective survey within the international liver tumor commu-
nity, the response to GEMOX was 30% in heavily pretreated 
pediatric patients (personal communication).
Adding GEMOX to sorafenib (n=83) increased 4-month 
PFS rate from 54% to 61% and median OS from 13 to 
13.5 months.27 Williet et al28 described a 61 year old man with 
HCC and lymph node metastasis treated with sorafenib and 
GEMOX, who achieved a PR and drop of α-fetoprotein to 
normal levels. The treatment resulted in a curative surgery. 
The experience within the GPOH with GEMOX given every 
14 days with sorafenib in-between further supports that this 
regimen is worth being evaluated in a prospective study in 
pediatric patients.
But still, new effective drugs besides the conventional che-
motherapeutic ones (eg, PLADO, GEMOX, and sorafenib) are 
definitely needed with the goal to achieve a higher response 
rate, thus translating into a higher surgical resection rate.
New agents in pediatric HCC
Since it is strongly believed that HCC in children is a different 
biologic disease, results from studies in the adult population 
cannot simply be translated to children.7,8 The better response 
to chemotherapy in pediatric patients may be due to the much 
higher rate of “de novo” tumors and normal liver function. In 
addition, in older children and in young adolescents, an entity 
called transitional liver cell tumor has been observed, which 
is made up  of chemotherapy-sensitive hepatoblastoma-like 
cells, cells similar to those of HCC, and intermediate cell 
forms.29 Young people more often present the fibrolamellar 
histologic variant.30 It was thought that this variant has a 
more favorable prognosis, but recently it was shown that the 
long-term OS is similar to that for HCC.31
Since HCCs are highly vascularized tumors with 
increased levels of VEGF, antiangiogenic approaches repre-
sent a potential new therapeutic strategy. In adults, but not 
in children, different antiangiogenic agents besides sorafenib 
have been tested in clinical studies, eg, sunitinib, brivanib, 
bevacizumab, and ramucirumab.32 For example, sunitinib was 
proven to be nonsuperior when randomized with sorafenib 
and was highly toxic, with side effects including thrombo-
cytopenia and neutropenia.33 Bevacizumab was the most 
promising agent, showing an objective response in six of 
46 patients (13%) and a PFS rate of 65% at 6 months.34 In 
combination with erlotinib (EGFR inhibitor), a response rate 
of 25% was reported.35 Despite the initial promising results, 
there were no plans for a Phase III study with bevacizumab.
EGFR inhibitors (eg, erlotinib or cetuximab),32 mTor 
inhibitors (eg, sirolimus),36 and MEK inhibitors (eg, 
 selumetinib)37 as single agents have not demonstrated sig-
nificant antitumor activity.
The HGF /c-MET pathway has been identified as hav-
ing an important role in tumor progression, angiogenesis, 
and appearance of metastases in HCC. Silencing the c-Met 
expression in cell lines and preclinical models was shown 
to inhibit HCC growth.38 However, only in patients with a 
high MET expression, tivantinib, a selective tyrosine kinase 
inhibitor, achieved a significantly longer median time to pro-
gression (1.4 vs 2.7 months), PFS (1.4 vs 2.2 months), and 
overall survival (3.8 vs 7.2 months).39 Cabozantinib (XL184), 
a dual tyrosine kinase inhibitor with activity against c-MET, 
VEGFR2, and RET, demonstrated a tumor control rate at 
week 12 of 71% in a randomized Phase II study.40 A 10 year 
old child was treated with relapsed HCC in complete remis-
sion with cabozantinib as maintenance therapy for 12 months. 
Two months later, the child relapsed again in the lung.
Immune checkpoint blockade has been presented as a 
new encouraging therapeutic option for various malignancies 
including HCC. Blocking of PD-1 with a specific antibody has 
been shown to amplify T-cell function and enhance antitumor 
effects.41 HCC is known to be an inflammation-associated can-
cer and can therefore be immunogenic.42 Upregulation of PD-1 
and the PD-1 immune checkpoint ligand (PD-L1) in HCC is 
associated with poor prognosis.43,44 In a Phase I/II study, PD-1 
blockade with nivolumab showed complete responses in two out 
of 39 patients (5%) and PRs in seven (18%) patients. OS rate 
was 72% at 6 months.45 These initial data support the continued 
exploration of nivolumab in HCC. The abovementioned 10 year 
old boy was treated for the second relapse with nivolumab and 
achieved a significant but temporary clinical response.
Current studies in adult cancer are ongoing, combining 
immune checkpoint inhibitors with targeted therapy or che-
motherapeutic agents such as anthracyclines or gemcitabine 
since these can also modulate T-cell proliferation and pro-
mote immunogenic cell death.41,46,47 This makes sense as 
monotherapy with targeted agents demonstrated an improved 
response rate but a limited time to tumor progression, whereas 
checkpoint blockade monotherapy seems to have a lower 
response rate but an extended PFS.48
Unfortunately, information about the feasibility or effects 
of those new agents is not available for childhood HCC. There-
fore, Phase I/II trials are urgently needed in childhood HCC.
Liver transplantation across the Milan 
criteria?
The indication for liver transplantation in adults is restricted 
to the Milan criteria, ie, the evidence of a single tumor <5 cm 
in size or no more than three foci with each not exceeding 3 
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cm and no vascular invasion or extrahepatic involvement.49 
The practice guidelines of the American Association for 
Transplantation and the North American Society for Pediatric 
Gastroeneterology, Hepatology, and Nutrition recommend 
that the indication for liver transplantation in childhood HCC 
must be discussed individually for each patient. In principle, 
liver transplantation should be considered in children with no 
extrahepatic tumor or gross vascular invasion on radiological 
imaging, irrespective of the size of the lesions or the number 
of the lesions.50 Successful transplantations have been done 
in children with more liberal criteria, even in patients with 
large, multifocal HCC, microscopic blood vessel involve-
ment, or limited extrahepatic tumor.51–53
A meta-analysis showed lower relapse rate and longer 
EFS and OS in patients treated with sirolimus compared 
with calcineurin inhibitor following liver transplantation 
for HCC.54
To conclude, the Milan criteria are not applicable for 
children with HCC. Individual decisions for a liver trans-
plantation have to be made.
TACE in pediatric HCC patients
Palliative TACE is a standard procedure in adults with 
solitary or multifocal HCC without extrahepatic metastases. 
However, in children, only few cases were reported. Back in 
2,000, Malogolowkin et al55 reported that all eleven children 
(18 months–14 years old) with unresectable, chemotherapy-
resistant liver tumors (three with HCC) responded – five 
(one with HCC) went on to surgical resection and three 
survived. The conclusion was that TACE with a suspension 
of cisplatin, doxorubicin, and mitomycin mixed with lipiodol 
is feasible, well-tolerated, and effective in achieving surgical 
resectability in pediatric patients. These encouraging results 
were confirmed by Czauderna et al56 (five patients, 1–12 years 
old, one with HCC).
Thus, TACE could be offered to patients with chemother-
apy-resistant liver tumor for palliative care or even with the 
goal of achieving surgical resectability and cure.
Conclusion
Research has to be done to characterize the molecular and 
genomic mechanisms of pediatric HCC to support the 
 development of novel therapeutic approaches and the imple-
mentation of personalized medicine. At the moment, it would 
be worth initiating clinical studies to evaluate bevacizumab 
combined with standard chemotherapy (PLADO or GEMOX 
with sorafenib), c-met inhibitors like cabozantinib in tumors 
with high MET expression, and immune checkpoint blockade 
agents like nivolumab.
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